Wittamer Valérie, Grégoire Françoise, Robberecht Patrick, Vassart Gilbert, Communi David, Parmentier Marc
Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, Brussels, Belgium.
J Biol Chem. 2004 Mar 12;279(11):9956-62. doi: 10.1074/jbc.M313016200. Epub 2003 Dec 29.
Chemerin is a novel protein identified as the natural ligand of ChemR23 (chemerinR), a previously orphan G protein-coupled receptor expressed in immature dendritic cells and macrophages. Chemerin is synthesized as a secreted precursor, prochemerin, which is poorly active, but converted into a full agonist of chemerinR by proteolytic removal of the last six amino acids. In the present work, we have synthesized a number of peptides derived from the C-terminal domain of human prochemerin and have investigated their functional properties as agonists or antagonists of human chemerinR. We found that the nonapeptide (149)YFPGQFAFS(157) (chemerin-9), corresponding to the C terminus of processed chemerin, retained most of the activity of the full-size protein, with regard to agonism toward the chemerinR. Extension of this peptide at its N terminus did not increase the activity, whereas further truncations rapidly resulted in inactive compounds. The C-terminal end of the peptide appeared crucial for its activity, as addition of a single amino acid or removal of two amino acids modified the potency by four orders of magnitude. Alanine-scanning mutagenesis identified residues Tyr(149), Phe(150), Gly(152), Phe(154), and Phe(156) as the key positions for chemerinR activation. A modified peptide (YHSFFFPGQFAFS) was synthesized and iodinated, and a radioligand binding assay was established. It was found that the ability of the various peptides to activate the chemerin receptor was strictly correlated with their affinity in the binding assay. These results confirm that a precise C-terminal processing is required for the generation of a chemerinR agonist. The possibility to restrict a medium sized protein to a nonapeptide, while keeping a low nanomolar affinity for its receptor is unusual among G protein-coupled receptors ligands. The identification of these short bioactive peptides will considerably accelerate the pharmacological analysis of chemerin-chemerinR interactions.
瑞马芬是一种新发现的蛋白质,被确定为ChemR23(瑞马芬受体)的天然配体,ChemR23是一种先前未被归类的G蛋白偶联受体,在未成熟的树突状细胞和巨噬细胞中表达。瑞马芬最初以分泌前体前瑞马芬的形式合成,其活性较低,但通过蛋白水解去除最后六个氨基酸后可转化为瑞马芬受体的完全激动剂。在本研究中,我们合成了一些源自人前瑞马芬C末端结构域的肽,并研究了它们作为人瑞马芬受体激动剂或拮抗剂的功能特性。我们发现,对应于加工后瑞马芬C末端的九肽(149)YFPGQFAFS(157)(瑞马芬-9),在对瑞马芬受体的激动作用方面保留了全长蛋白的大部分活性。在该肽的N末端进行延伸并未增加其活性,而进一步截短则迅速导致无活性的化合物。该肽的C末端对于其活性似乎至关重要,因为添加单个氨基酸或去除两个氨基酸会使效力改变四个数量级。丙氨酸扫描诱变确定酪氨酸(149)、苯丙氨酸(150)、甘氨酸(152)、苯丙氨酸(154)和苯丙氨酸(156)残基是瑞马芬受体激活的关键位置。合成并碘化了一种修饰肽(YHSFFFPGQFAFS),并建立了放射性配体结合测定法。发现各种肽激活瑞马芬受体的能力与其在结合测定中的亲和力密切相关。这些结果证实,生成瑞马芬受体激动剂需要精确的C末端加工。在G蛋白偶联受体配体中,将一种中等大小的蛋白质限制为九肽,同时对其受体保持低纳摩尔亲和力的情况并不常见。这些短生物活性肽的鉴定将大大加速瑞马芬 - 瑞马芬受体相互作用的药理学分析。